To our knowledge, this is the first study to comprehensively summarize the cost-effectiveness of all available first-line treatments for patients with advanced EGFR mutated NSCLC from the UK and China’s health care system perspective. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.